X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
multiple sclerosis (9) 9
index medicus (8) 8
neurosciences (7) 7
clinical neurology (5) 5
immunology (4) 4
management (4) 4
oral fingolimod (4) 4
research (4) 4
double-blind (3) 3
drug therapy (3) 3
fty720 (3) 3
humans (3) 3
lymphocytes (3) 3
natalizumab (3) 3
neurology (3) 3
original research (3) 3
therapy (3) 3
4-aminopyridine (2) 2
adult (2) 2
analysis (2) 2
antibodies (2) 2
arm function (2) 2
cellular and molecular neuroscience (2) 2
csf (2) 2
dalfampridine (2) 2
disability (2) 2
fampridine (2) 2
female (2) 2
fingolimod (2) 2
immunity (2) 2
immunoassay (2) 2
male (2) 2
middle aged (2) 2
monitoring (2) 2
multiple sclerosis - blood (2) 2
pharmacology & pharmacy (2) 2
quality-of-life (2) 2
sphingosine 1-phosphate (2) 2
treatment outcome (2) 2
trial (2) 2
111 (1) 1
112 (1) 1
610 medicine & health (1) 1
adhesion (1) 1
administration, oral (1) 1
alemtuzumab (1) 1
angeborene immunität, dendritische zellen, antigen-präsentierende zellen, sphingosin-1-phosphat-gerichtete therapien, multiple sklerose, technische universität dresden, publikationsfonds (1) 1
antibodies - pharmacology (1) 1
antigen-presenting cells (1) 1
antigens, cd (1) 1
article (1) 1
b cells (1) 1
b-cell (1) 1
b-cells (1) 1
biomarker (1) 1
biomedicine (1) 1
blood (1) 1
body regions (1) 1
brain volume loss (1) 1
breast milk (1) 1
breast-milk (1) 1
cd14 antigen (1) 1
cd19 antigen (1) 1
cd3 antigen (1) 1
cd4 antigen (1) 1
cd8 antigen (1) 1
cell proliferation - drug effects (1) 1
cell proliferation - physiology (1) 1
cells (1) 1
central nervous system (1) 1
central-nervous-system (1) 1
cerebrospinal fluid (1) 1
cerebrospinal-fluid (1) 1
cessation (1) 1
clinical practice (1) 1
clinical trials (1) 1
clinical trials as topic (1) 1
clinical-practice (1) 1
clinically meaningful (1) 1
cns (1) 1
cognition (1) 1
controlled trial (1) 1
correlation analysis (1) 1
dendritic cell-migration (1) 1
dendritic cells (1) 1
depression (1) 1
depressive symptoms (1) 1
diagnosis (1) 1
disability evaluation (1) 1
disease-activity (1) 1
disease-modifying therapies (1) 1
distinct (1) 1
dosage and administration (1) 1
dose-response relationship, drug (1) 1
efficacy (1) 1
elisa (1) 1
endocrine system (1) 1
experimental autoimmune encephalomyelitis (1) 1
exposure (1) 1
expression (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of neurology, ISSN 0340-5354, 07/2019, pp. 1 - 12
Secondary progressive multiple sclerosis (SPMS) is the second most common form of multiple sclerosis (MS). One in two relapse remitting multiple sclerosis... 
Multiple sclerosis | Diagnosis
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 5/2018, Volume 24, Issue 6, pp. 820 - 822
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 04/2019, p. 135245851983770
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 9/2018, Volume 24, Issue 10, pp. 1337 - 1346
Objective: The primary objective of this real-world study was to describe the response to fampridine and changes of gait parameters in multiple sclerosis (MS)... 
4-aminopyridine | Multiple sclerosis | walking dynamics | fampridine | treatment response | walking capacity | CLINICALLY MEANINGFUL | WALKING | DALFAMPRIDINE | ARM FUNCTION | SUSTAINED-RELEASE FAMPRIDINE | NEUROSCIENCES | CLINICAL NEUROLOGY | PROGRESSIVE MULTIPLE-SCLEROSIS | TRIAL | DOUBLE-BLIND | DISABILITY | QUALITY-OF-LIFE | Walking | Gait | Patients
Journal Article
Neurology, ISSN 0028-3878, 10/2018, Volume 91, Issue 18, pp. 849 - 850
Journal Article
Frontiers in Immunology, ISSN 1664-3224, 11/2018, Volume 9, p. 2669
Objective: Fingolimod is approved for the treatment of highly active relapsing remitting multiple sclerosis (MS) patients and acts by its unique mechanism of... 
lymphocyte subsets | real world lab data | monitoring | fingolimod | lymphopenia | FREQUENCIES | MULTIPLE-SCLEROSIS PATIENTS | INDUCED LYMPHOPENIA | ORAL FINGOLIMOD | MANAGEMENT | PLACEBO-CONTROLLED PHASE-3 | PERIPHERAL-BLOOD | IMMUNOLOGY | B-CELLS | FTY720 | MEMORY T-CELLS | Multiple sclerosis | Fingolimod | Lymphocytes | Dosage and administration | B cells | Research | Drug therapy
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 10/2018, Volume 24, Issue 12, pp. 1627 - 1634
Background: Managing medication during pregnancy and lactation in multiple sclerosis (MS) patients needs to balance potential risks to the newborn with the... 
breast milk | Multiple sclerosis | newborn | relapsing remitting | natalizumab | pregnancy | IMMUNITY | MOTHER | NEUROSCIENCES | BREAST-MILK | CLINICAL NEUROLOGY | FC-RECEPTOR | OUTCOMES | EXPRESSION | EXPOSURE
Journal Article
FRONTIERS IN NEUROLOGY, ISSN 1664-2295, 12/2018, Volume 9, p. 1071
Natalizumab inhibits the transmigration of immune cells across the blood-brain barrier thus inhibiting inflammation in the central nervous system. Generally,... 
ANTIBODIES | INTEGRIN VLA-4 | peripheral immune cell subtypes | CONTROLLED TRIAL | MANAGEMENT | multiple sclerosis | DISTINCT | clinical practice | NEUROSCIENCES | CLINICAL NEUROLOGY | real-world lab data | ADHESION | THERAPY | B-CELL | RELEVANCE | natalizumab | LYMPHOCYTES | Clinical trials | Treatment outcome | Multiple sclerosis | Research | Drug therapy | Analysis
Journal Article
Multiple sclerosis (Houndmills, Basingstoke, England), 04/2019, p. 1352458519837702
Journal Article
Therapeutic Advances in Chronic Disease, ISSN 2040-6223, 4/2019, Volume 10, pp. 1 - 11
Objectives: Mobility impairments constitute a long-term burden in patients with multiple sclerosis (MS). Currently there is evidence that the drug fampridine... 
DEPRESSION | DALFAMPRIDINE | cognition | LOWER-BODY FUNCTION | multiple sclerosis | ARM FUNCTION | depressive symptoms | TRIAL | 4-aminopyridine | fatigue | DOUBLE-BLIND | DISABILITY | PHARMACOLOGY & PHARMACY | fampridine | SLOW-RELEASE-FAMPRIDINE | QUALITY-OF-LIFE | quality of life | upper extremity
Journal Article
Neurology: Neuroimmunology & Neuroinflammation, ISSN 2332-7812, 05/2019, Volume 6, Issue 3, p. e555
OBJECTIVETo evaluate individual neurofilament light chain (NfL) variation over the time of disease course and the potential of NfL measurement to predict... 
ALEMTUZUMAB | REMITTING MULTIPLE-SCLEROSIS | MANAGEMENT | THERAPY | BIOMARKER | LIGHT-CHAIN | INTERFERON-BETA | IMMUNOASSAY | NEUROSCIENCES | CLINICAL NEUROLOGY | DISEASE-ACTIVITY | ELISA
Journal Article
Journal of Neuroinflammation, 01/2017, Volume 14
Background Growing evidence emphasizes the relevance of sphingolipids for metabolism and immunity of antigen-presenting cells (APC). APCs are key players in... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.